NEW YORK (GenomeWeb) – Precision Therapeutics announced today that it has signed a definitive agreement to merge with Helomics.

Under the terms of the deal, Precision — formerly Skyline Medical — will acquire the 75 percent of Helmomics' shares it does not currently own, having already taken a 25 percent equity stake in the firm in December.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar
14

In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.